CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $32.47M, above the global median of $18.73M
- FinancialsAltman Z-Score -2.64: distress zone
- Interpretations11 currently firing — 11
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
504.33MUSDvs all stocks (USD)
Trailing P/E
19.16xvs Biotechnology peers
Revenue (TTM)
231.24MUSDvs all stocks (USD)
Profit Margin
11.55%vs Biotechnology peers
Beta
1.23xvs all stocks
52-Week Change
93.46%vs all stocks
Market Capitalization
504.33MUSDvs all stocks (USD)
Enterprise Value
415.24MUSDvs all stocks (USD)
Trailing P/E
19.16xvs Biotechnology peers
Forward P/E
27.91xvs Biotechnology peers
PEG Ratio
0.5747xvs Biotechnology peers
Price to Sales (TTM)
2.18xvs Biotechnology peers
Price to Book (MRQ)
3.60xvs Biotechnology peers
Enterprise to Revenue
1.80xvs Biotechnology peers
Enterprise to EBITDA
10.35xvs Biotechnology peers
Gross Margin
77.92%vs Biotechnology peers
Profit Margin
11.55%vs Biotechnology peers
Operating Margin
13.42%vs Biotechnology peers
Return on Assets (TTM)
9.81%vs Biotechnology peers
Return on Equity (TTM)
21.97%vs Biotechnology peers
Revenue (TTM)
231.24MUSDvs all stocks (USD)
Revenue per Share (TTM)
4.57USDUpdated Sep 28, 2026Quarterly Revenue Growth
7.80%vs Biotechnology peers
Gross Profit (TTM)
173.04MUSDvs all stocks (USD)
EBITDA (TTM)
53.34MUSDvs all stocks (USD)
Net Income (TTM)
26.72MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
39.90%vs Biotechnology peers
Operating Cash Flow (TTM)
41.15MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
32.47MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
228.37MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
58.16MUSDFY2025 · Dec 31, 2025Gross Profit
170.21MUSDFY2025 · Dec 31, 2025Operating Income
37.30MUSDvs all stocks (USD)
Pre-tax Income
35.78MUSDFY2025 · Dec 31, 2025Income Tax Expense
4.67MUSDFY2025 · Dec 31, 2025Net Income
31.11MUSDFY2025 · Dec 31, 2025EBIT
42.40MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
53.34MUSDFY2025 · Dec 31, 2025Research & Development
62.07MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
71.21MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.08MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
6.62MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.6200USDFY2025 · Dec 31, 2025EPS (Diluted)
0.6100USDFY2025 · Dec 31, 2025Basic Shares Outstanding
50.01MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
50.01MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
31.11MUSDFY2025 · Dec 31, 2025Operating Cash Flow
29.33MUSDFY2025 · Dec 31, 2025Free Cash Flow
29.26MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
31.73MUSDFY2025 · Dec 31, 2025Income Tax Paid
1.52MUSDFY2025 · Dec 31, 2025Interest Paid
5.82MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
31.11MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
10.94MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
3.25MUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.94MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-21.28MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-453.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.17MUSDFY2025 · Dec 31, 2025Capital Expenditures
-71.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-108.14MUSDFY2025 · Dec 31, 2025Sale of Investments
72.02MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-36.19MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-44.44MUSDFY2025 · Dec 31, 2025Other Financing Charges
-888.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-45.33MUSDFY2025 · Dec 31, 2025Shares Outstanding
51.10MSharesUpdated Sep 28, 2026Float Shares
39.64MSharesUpdated Sep 28, 2026Shares Short
4.32MSharesUpdated Sep 28, 2026Short Ratio
14.60daysvs all stocks
Short % of Shares Outstanding
9.80%vs all stocks
% Held by Insiders
15.28%vs all stocks
% Held by Institutions
75.68%vs all stocks
Total Cash (MRQ)
93.90MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.82USDUpdated Sep 28, 2026Total Debt (MRQ)
4.82MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0348xvs Biotechnology peers
Current Ratio (MRQ)
2.91xvs Biotechnology peers
Book Value per Share (MRQ)
2.71USDUpdated Sep 28, 2026Total Assets
216.30MUSDvs all stocks (USD)
Total Current Assets
162.69MUSDFY2025 · Dec 31, 2025Total Liabilities
85.96MUSDFY2025 · Dec 31, 2025Total Non-current Assets
53.62MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
4.71MUSDFY2025 · Dec 31, 2025Total Current Liabilities
81.25MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
29.64MUSDFY2025 · Dec 31, 2025Other Short-term Investments
67.89MUSDFY2025 · Dec 31, 2025Accounts Receivable
53.65MUSDFY2025 · Dec 31, 2025Inventory
5.51MUSDFY2025 · Dec 31, 2025Accounts Payable
5.06MUSDFY2025 · Dec 31, 2025Short-term Debt
23.84MUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.33MUSDFY2025 · Dec 31, 2025Long-term Debt
4.71MUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.28BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
130.34MUSDvs all stocks (USD)
52-Week Low
4.58USDUpdated Sep 28, 202652-Week High
9.98USDUpdated Sep 28, 202652-Week Change
93.46%vs all stocks
Beta
1.23xvs all stocks
50-Day MA
8.88USDUpdated Sep 28, 2026200-Day MA
7.37USDUpdated Sep 28, 2026Avg 10-Day Volume
307.23KSharesUpdated Sep 28, 2026Avg 30-Day Volume
298.32KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
0.5100USDUpdated Sep 28, 2026Other Income / Expense
1.03MUSDFY2025 · Dec 31, 202511 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Debt Falling While Share Count Rises
Debt has fallen for four years while the share count rose over eight.
Reads
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Diagnostic
Efficiency from Aging Assets
Revenue per asset reads high, partly because those assets are largely written down.
Reads
Diagnostic
Underinvestment Cash Flow
Less of its cash flow goes to capex than at most of its peers, on an asset base already largely written down.
Reads
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Low Fixed-Asset Share With Elevated Turnover
It owns few buildings and machines, yet gets more sales and profit from its assets than its industry does.
Reads
Three-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA
Three years of positive free cash flow, with the 50-week average above the 200-week.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.91Altman Z-Score: -2.64
Financial Health
Altman Z-Score -2.64: distress zoneCritical
Altman Z-Score: -2.64
High structural barrier to entryNotable
Barrier to Entry: 0.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $32.47M, above the global median of $18.73MNotable
Levered free cash flow (USD): 32,473,124Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Boryung Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pacific Biosciences of California, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Bioperfectus Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Ever Supreme Bio Technology Co., Ltd
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bright Minds Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Succeeder Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ningbo David Medical Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangsu Hanbon Science & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hinova Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Oculis Holding AG
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
ASPEED Technology Inc.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMAThree Asset-Base Ratios Elevated
MiMedx Group, Inc.
9 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedEfficiency from Aging AssetsIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow Fixed-Asset Share With Elevated TurnoverUnderinvestment Cash FlowThree Asset-Base Ratios Elevated
Thyrocare Technologies Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMAThree Asset-Base Ratios Elevated